BCR-ABL1 Quantification by DD PCR Test is a highly precise diagnostic procedure used to monitor the levels of the BCR-ABL1 fusion gene, a marker commonly associated with chronic myeloid leukemia (CML) and, in some cases, acute lymphoblastic leukemia (ALL). This test employs Droplet Digital PCR (ddPCR) technology, which allows for an extremely accurate quantification of the BCR-ABL1 gene transcripts, providing essential information for the diagnosis, prognosis, and monitoring of therapeutic response in patients with these hematologic malignancies.
Conducted at DNA Labs UAE, a facility renowned for its state-of-the-art diagnostic services, the BCR-ABL1 Quantification by DD PCR Test is pivotal for clinicians in tailoring the most effective treatment plans for their patients. By precisely measuring the amount of BCR-ABL1 gene expression, healthcare providers can assess the disease's progression, evaluate the effectiveness of specific therapies, and adjust treatment strategies accordingly.
The cost of the BCR-ABL1 Quantification by DD PCR Test at DNA Labs UAE is set at 1800 AED. This investment is crucial for those affected by conditions linked to the BCR-ABL1 gene, as it empowers patients and their healthcare teams with vital data to make informed decisions throughout the course of the disease and treatment.
The BCR-ABL1 Quantitative p210/p190/p230 Test is a highly specialized diagnostic examination offered by DNA Labs UAE, designed to detect the presence and measure the amount of the BCR-ABL1 fusion gene in a patient's blood or bone marrow. This fusion gene is a hallmark of chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL), resulting from the translocation between chromosomes 9 and 22, known as the Philadelphia chromosome. The test specifically targets the three main types of BCR-ABL1 fusion proteins: p210, p190, and p230, each associated with different forms of leukemia.
The quantitative nature of this test allows for the precise monitoring of disease progression and response to therapy, making it an invaluable tool in the management of patients with CML and ALL. By measuring the levels of BCR-ABL1 over time, healthcare providers can adjust treatment strategies to achieve the best possible outcomes.
At DNA Labs UAE, the BCR-ABL1 Quantitative p210/p190/p230 Test is offered for 1800 AED. The test is conducted with state-of-the-art technology and under the guidance of experienced professionals, ensuring accurate and reliable results. Given its critical role in the diagnosis and management of leukemia, this test represents a significant investment in patient care, providing essential information for personalized treatment planning.
The "Beta Thalassemia - 12 Common Mutations Screening Single Test," available at DNA Labs UAE, is a specialized genetic test designed to detect the 12 most common mutations associated with Beta Thalassemia, a blood disorder that reduces the production of hemoglobin. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen to cells throughout the body. Individuals with Beta Thalassemia may experience a range of symptoms from mild anemia to severe health complications, depending on the mutation and its impact on hemoglobin production.
This test is particularly important for individuals with a family history of thalassemia or those belonging to ethnic groups with a high prevalence of the disease. Early detection through this screening can provide crucial information for disease management, treatment planning, and informed family planning decisions. The test involves a simple blood draw, and the sample is analyzed to identify any of the 12 common mutations linked to Beta Thalassemia.
Offered at a cost of 1800 AED, the test is a valuable tool for at-risk individuals seeking to understand their genetic health and make proactive decisions regarding their well-being and that of their future offspring. DNA Labs UAE, known for its state-of-the-art genetic testing services, ensures confidentiality, accuracy, and timely results for all its clients.
The BKJC Qualitative PCR Test is a sophisticated diagnostic procedure designed to detect the presence of BK virus in patients, utilizing the highly accurate Polymerase Chain Reaction (PCR) methodology. This test is particularly vital for individuals who are at an increased risk of BK virus-related complications, such as transplant recipients and those with weakened immune systems. By targeting the genetic material of the virus, the PCR technique ensures a high level of sensitivity and specificity, making it a reliable tool for early detection and management of BK virus infections.
Conducted at DNA Labs UAE, a leading facility known for its advanced diagnostic technologies and expert staff, the test ensures that patients receive precise and timely results. The cost of the BKJC Qualitative PCR Test is set at 1800 AED, reflecting the intricate technology and professional expertise involved in the testing process. This investment is crucial for at-risk individuals, providing them with critical information that can guide treatment decisions and potentially prevent severe outcomes associated with BK virus infections.
The BRAF Mutation Analysis V600E Test is a specialized diagnostic procedure aimed at detecting the V600E mutation within the BRAF gene. This mutation is significant because it is frequently associated with various types of cancer, including melanoma, thyroid cancer, and colorectal cancer. Identifying the presence of this mutation can help in tailoring the most effective treatment strategies for patients, as it often indicates responsiveness to specific targeted therapies.
Performed at DNA Labs UAE, a reputable facility known for its advanced genetic testing capabilities, this test offers a reliable means of genetic analysis. The process involves collecting a sample of the patient's tissue or blood, which is then subjected to sophisticated molecular techniques to scrutinize the BRAF gene for the specific V600E mutation.
The cost of the BRAF Mutation Analysis V600E Test at DNA Labs UAE is 1800 AED. This price reflects the intricate technology and expertise required to accurately identify this genetic variation. For patients and healthcare providers, the test represents a crucial step in the journey towards personalized medicine, enabling more precise and effective cancer treatment plans based on an individual's genetic makeup.
The "CALR Mutation Analysis Deletion or Insertion in Exon 9 Test" is a specialized diagnostic procedure offered by DNA Labs UAE, designed to detect specific mutations within exon 9 of the CALR gene. These mutations are primarily associated with certain types of blood disorders, including myeloproliferative neoplasms (MPNs) like essential thrombocythemia (ET) and primary myelofibrosis (PMF). The test specifically looks for deletions or insertions within this region of the CALR gene, which can have significant implications for disease prognosis and treatment strategies.
Performed in a state-of-the-art laboratory setting, this analysis involves extracting DNA from a patient's blood sample and employing sophisticated molecular techniques to scrutinize the exon 9 of the CALR gene for any aberrations. Identifying the presence of these mutations is crucial for confirming the diagnosis, aiding in risk stratification, and guiding the selection of appropriate therapeutic approaches.
The cost of the "CALR Mutation Analysis Deletion or Insertion in Exon 9 Test" at DNA Labs UAE is set at 1800 AED. This investment covers the comprehensive testing process, from sample collection to detailed genetic analysis, ensuring accurate and reliable results. Patients undergoing this test can expect a thorough examination of their CALR gene status, providing essential insights into their condition and facilitating personalized medical care.
The CCND1 Test is a specialized diagnostic procedure designed to identify alterations in the CCND1 gene, which can have significant implications for understanding various medical conditions, including certain types of cancers. This gene plays a crucial role in cell cycle regulation, and its abnormal expression or mutation can lead to uncontrolled cell growth, a hallmark of cancerous transformations. By analyzing the CCND1 gene, healthcare professionals can gain valuable insights into the molecular underpinnings of a patient's condition, guiding treatment decisions and prognostic assessments.
Conducted at DNA Labs UAE, a leading facility in genetic and molecular diagnostics, the test ensures accuracy and reliability in results, employing state-of-the-art technology and methodologies. The cost of the CCND1 Test at DNA Labs UAE is set at 1800 AED, reflecting the intricate processes and expertise required to accurately detect and interpret genetic variations in the CCND1 gene. Patients undergoing this test can expect a comprehensive analysis, contributing to a more personalized and effective approach to their healthcare management.
The CEBPA Full Gene Mutation Analysis Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the CEBPA gene. This gene plays a critical role in the development and function of certain types of white blood cells, and mutations in CEBPA are associated with an increased risk of developing acute myeloid leukemia (AML), a type of cancer that affects the blood and bone marrow.
The test involves a detailed examination of the CEBPA gene to detect any abnormalities or mutations. It is particularly useful for patients who have been diagnosed with AML, as the presence of CEBPA mutations can influence treatment decisions and prognosis. The test can also be used for individuals with a family history of AML or related blood disorders, as part of a comprehensive genetic assessment.
Performed at the state-of-the-art facilities of DNA Labs UAE, the CEBPA Full Gene Mutation Analysis Test is conducted by a team of experienced geneticists and laboratory technicians. The cost of the test is 1800 AED, reflecting the sophisticated technology and expertise required to accurately identify mutations in the CEBPA gene.
For patients and families facing the challenges of AML, this test offers valuable insights into the genetic factors influencing the disease, enabling more personalized and effective treatment strategies.
Chromosome Breakage Syndrome Test, offered by DNA Labs UAE, is a specialized diagnostic procedure aimed at identifying chromosomal abnormalities that predispose individuals to various genetic disorders. This test is particularly vital for detecting conditions characterized by an increased susceptibility to chromosome breakage, which can lead to cancer, developmental delays, and other severe health issues. At a cost of 1800 AED, the test involves analyzing the individual's DNA to identify any anomalies in chromosome structure or function that could indicate the presence of a chromosome breakage syndrome, such as Fanconi anemia or Bloom syndrome. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test provides crucial insights into the genetic health of an individual, facilitating early intervention and personalized medical strategies to manage or mitigate the impact of these genetic disorders.
The C-Myc Oncogene Test is a specialized diagnostic procedure designed to detect abnormalities in the MYC gene, which is often implicated in the development of various types of cancer. The MYC gene plays a crucial role in cell growth, division, and apoptosis; hence, its dysregulation can lead to uncontrolled cell proliferation, a hallmark of cancer. This test is particularly useful for identifying specific genetic mutations associated with the MYC oncogene, providing critical information that can influence treatment decisions and prognosis.
Performed at DNA Labs UAE, a leading facility in genetic testing and analysis, the test offers precise and reliable results. With state-of-the-art technology and a team of experienced professionals, DNA Labs UAE ensures the highest standards of accuracy and confidentiality in testing.
The cost of the C-Myc Oncogene Test at DNA Labs UAE is 1800 AED. This investment in health can be invaluable for patients at risk of cancers associated with the MYC oncogene, enabling early detection and potentially more effective treatment options. It's important for patients to consult with their healthcare provider to understand the implications of the test results and the best course of action based on those results.
